You are here: Home ยป Archives for Financing Agreements

Antalpha Anchors $150 Million Financing in Aurelion Treasury; Initiating NASDAQ’s First Tether Gold Treasury

Prestige Wealth Inc. (NASDAQ: PWM) Plans to be Renamed to Aurelion Inc. (NASDAQ: AURE) Subject to Approvals
$100 Million Private Placement & $50 Million Senior Debt Facility
Antalpha Anchors Aurelion Treasury, Exclusively in Tether Gold (XAU₮) for Resilience and Transparency

SINGAPORE, Oct. 11, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha”), a leading institutional digital asset financing platform, today announced that it has invested approximately $43 million as lead investor and acquired controlling voting rights in Prestige Wealth Inc. (NASDAQ: PWM; AURE) (“Aurelion” or the “Company”) through participation in a committed private investment in public equity (“PIPE”), alongside accredited investors including TG Commodities S.A. de C.V. (“Tether”) and Kiara Capital Holding Limited (“Kiara Capital”), invested by Antalpha’s management. The Company (NASDAQ: PWM) is expected to be renamed as “Aurelion Inc.”, subject to approvals, and will trade under the new ticker (NASDAQ: AURE) beginning Monday, October 13, 2025.

“We are excited to collaborate with Tether, the largest stablecoin company in the world, to expand the trusted digital gold ecosystem. Digital assets will be more tangible to many when one can walk into a jewelry store and redeem a gold bar with Tether Gold (XAU₮). Through Antalpha RWA Hub, we hope to deliver new capabilities and services like this that will increase the liquidity and product offerings of Tether Gold (XAU₮),” said Paul Liang, CFO of Antalpha.

“Adding to Antalpha RWA Hub, we are excited to anchor Aurelion Treasury, the first pure–play NASDAQ Tether Gold (XAU₮) Treasury, to increase access to tokenized gold, which has strategic importance in the digital asset world. People and institutions need a safe haven to safeguard against inflation, fiat currency devaluation and crypto volatility. As a leading digital asset financing platform, Antalpha has common interest to fortify our own balance sheet with a significant gold reserve through Tether Gold (XAU₮) to improve collateral resilience,” continued Paul Liang.

Strategic Rationale
Antalpha Reserve 2.0 builds on Antalpha’s pilot program earlier this year when it acquired $20 million of Tether Gold (XAU₮). In early October, we announced a collaboration with Tether to launch Antalpha RWA Hub to increase access to Tether Gold (XAU₮). The $43 million PIPE lead investment in Aurelion Treasury represents the next phase of Reserve 2.0: scaling Antalpha’s Tether Gold (XAU₮) reserve with institutional infrastructure, governance and transparency.

Gold has served as the ultimate benchmark of value for more than 5,000 years, consistently providing a natural hedge amid macroeconomic volatility and political uncertainty. Its negative correlation to the U.S. dollar index (DXY) amidst global crises and inflationary cycles as well as serving as a safe haven to crypto volatility highlight the value of gold on the blockchain.

Tether Gold (XAU₮) addresses these vulnerabilities by being 100% physically backed and redeemable for LBMA–standard bullions stored in Switzerland. Since launching in 2020, approximately 7 tons of gold have been acquired to back Tether Gold (XAU₮), providing institutional–grade transparency, verifiability and liquidity. By committing to Tether Gold (XAU₮) as Aurelion’s sole treasury reserve, Antalpha aims to smooth volatility, preserve liquidity and increase collateral resilience, which supports Antalpha’s management philosophy of risk management first.

Transaction Highlights
Antalpha invested approximately $43 million in Aurelion’s approximately $100 million PIPE, along with accredited investors, including Kiara Capital for $6 million and Tether for $15 million. Following this transaction, Antalpha holds a stake of approximately 32.4% (or approximately 73.1% of the voting rights) and Kiara Capital holds a stake of approximately 8.6% (or approximately 18.9% of the voting rights) in Aurelion, based on the Company’s outstanding shares and assuming no exercise of PIPE warrants. With plans to continue fundraising to purchase additional Tether Gold (XAU₮), Aurelion believes its concentrated shareholding can provide more stability and ensure smoother operations.

Conference Call Information
Antalpha leadership will host a conference call at 8:30 am U.S. Eastern Standard Time on October 14, 2025 to discuss the transaction.

To attend, please register in advance at: https://register–conf.media–server.com/register/BIdf5d33a26d64454da01f41f3d6c9610e. Upon registration, you will receive the dial–in number, passcode, and your unique access PIN, as well as an email with a calendar invite.

A live webcast can be accessed at https://edge.media–server.com/mmc/p/bt67nb59.

A replay of the conference call will also be available on the Company’s investor relations website at https://ir.antalpha.com.

About Antalpha
Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to institutions in the digital asset industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real–time data.

About Aurelion
Aurelion is NASDAQ’s first Tether Gold (XAU₮) treasury. It combines the stability of physical gold with the efficiency of blockchain, providing investors access to tokenized gold reserve that could serve as a safe haven to inflation, currency devaluation and crypto volatility. In parallel, Aurelion will continue its wealth management and asset management services.

About Tether Gold (XAU₮)
Tether Gold (XAU₮) is a digital asset offered by TG Commodities S.A. de C.V. One full XAU₮ token represents one troy fine ounce of gold on a London Good Delivery bar. XAU₮ is available as an ERC–20 token on the Ethereum blockchain. The token can be traded or moved easily 24/7. XAU₮ allocated gold is identifiable with a unique serial number, purity, and weight, and is redeemable.

About Antalpha RWA Hub
Antalpha RWA Hub is Antalpha's dedicated Real–World Assets (“RWA”) infrastructure platform, currently focused on providing liquidity and services for gold–based RWAs.

Contacts
Investor Contact: [email protected] 

Safe Harbor Statement
This press release contains statements that may constitute “forward–looking” statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward–looking statements can be identified by terminology such as: “anticipate,” “aspire,” “intend,” “plan,” “offer,” “goal,” “objective,” “potential,” “seek,” “believe,” “project,” “estimate,” “expect,” “forecast,” “assume,” “strategy,” “target,” “trend,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the relevant business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions, including the anticipated performance of gold, Tether Gold (XAU₮), and any other Gold–related product, and Antalpha and Aurelion’s intention to purchase additional XAU₮. These statements are not historical facts nor assurance of future performance, and include, among others, statements regarding Antalpha’s investment in the Company through the PIPE financing, integration plans, anticipated benefits of the transaction, and Antalpha’s Reserve 2.0 digital treasury strategy. Forward–looking statements also include expectations regarding the purchase, holding, and management of XAU₮, and potential future capital deployment.

Forward–looking statements involve inherent risks and uncertainties that may cause actual results to differ materially, including regulatory review, integration challenges, market price volatility of XAU₮, liquidity risks, counterparty and custodial risks, technological and regulatory developments, accounting treatment, and other factors described in Antalpha’s filings with the SEC. All information in this press release is provided as of the date hereof, and Antalpha undertakes no duty to update any forward–looking statements except as required under applicable law.


GLOBENEWSWIRE (Distribution ID 9544075)

Antalpha Anchors $150 Million Financing in Aurelion Treasury; Initiating NASDAQ’s First Tether Gold Treasury

Prestige Wealth Inc. (NASDAQ: PWM) Plans to be Renamed to Aurelion Inc. (NASDAQ: AURE) Subject to Approvals
$100 Million Private Placement & $50 Million Senior Debt Facility
Antalpha Anchors Aurelion Treasury, Exclusively in Tether Gold (XAU₮) for Resilience and Transparency

SINGAPORE, Oct. 11, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha”), a leading institutional digital asset financing platform, today announced that it has invested approximately $43 million as lead investor and acquired controlling voting rights in Prestige Wealth Inc. (NASDAQ: PWM; AURE) (“Aurelion” or the “Company”) through participation in a committed private investment in public equity (“PIPE”), alongside accredited investors including TG Commodities S.A. de C.V. (“Tether”) and Kiara Capital Holding Limited (“Kiara Capital”), invested by Antalpha’s management. The Company (NASDAQ: PWM) is expected to be renamed as “Aurelion Inc.”, subject to approvals, and will trade under the new ticker (NASDAQ: AURE) beginning Monday, October 13, 2025.

“We are excited to collaborate with Tether, the largest stablecoin company in the world, to expand the trusted digital gold ecosystem. Digital assets will be more tangible to many when one can walk into a jewelry store and redeem a gold bar with Tether Gold (XAU₮). Through Antalpha RWA Hub, we hope to deliver new capabilities and services like this that will increase the liquidity and product offerings of Tether Gold (XAU₮),” said Paul Liang, CFO of Antalpha.

“Adding to Antalpha RWA Hub, we are excited to anchor Aurelion Treasury, the first pure–play NASDAQ Tether Gold (XAU₮) Treasury, to increase access to tokenized gold, which has strategic importance in the digital asset world. People and institutions need a safe haven to safeguard against inflation, fiat currency devaluation and crypto volatility. As a leading digital asset financing platform, Antalpha has common interest to fortify our own balance sheet with a significant gold reserve through Tether Gold (XAU₮) to improve collateral resilience,” continued Paul Liang.

Strategic Rationale
Antalpha Reserve 2.0 builds on Antalpha’s pilot program earlier this year when it acquired $20 million of Tether Gold (XAU₮). In early October, we announced a collaboration with Tether to launch Antalpha RWA Hub to increase access to Tether Gold (XAU₮). The $43 million PIPE lead investment in Aurelion Treasury represents the next phase of Reserve 2.0: scaling Antalpha’s Tether Gold (XAU₮) reserve with institutional infrastructure, governance and transparency.

Gold has served as the ultimate benchmark of value for more than 5,000 years, consistently providing a natural hedge amid macroeconomic volatility and political uncertainty. Its negative correlation to the U.S. dollar index (DXY) amidst global crises and inflationary cycles as well as serving as a safe haven to crypto volatility highlight the value of gold on the blockchain.

Tether Gold (XAU₮) addresses these vulnerabilities by being 100% physically backed and redeemable for LBMA–standard bullions stored in Switzerland. Since launching in 2020, approximately 7 tons of gold have been acquired to back Tether Gold (XAU₮), providing institutional–grade transparency, verifiability and liquidity. By committing to Tether Gold (XAU₮) as Aurelion’s sole treasury reserve, Antalpha aims to smooth volatility, preserve liquidity and increase collateral resilience, which supports Antalpha’s management philosophy of risk management first.

Transaction Highlights
Antalpha invested approximately $43 million in Aurelion’s approximately $100 million PIPE, along with accredited investors, including Kiara Capital for $6 million and Tether for $15 million. Following this transaction, Antalpha holds a stake of approximately 32.4% (or approximately 73.1% of the voting rights) and Kiara Capital holds a stake of approximately 8.6% (or approximately 18.9% of the voting rights) in Aurelion, based on the Company’s outstanding shares and assuming no exercise of PIPE warrants. With plans to continue fundraising to purchase additional Tether Gold (XAU₮), Aurelion believes its concentrated shareholding can provide more stability and ensure smoother operations.

Conference Call Information
Antalpha leadership will host a conference call at 8:30 am U.S. Eastern Standard Time on October 14, 2025 to discuss the transaction.

To attend, please register in advance at: https://register–conf.media–server.com/register/BIdf5d33a26d64454da01f41f3d6c9610e. Upon registration, you will receive the dial–in number, passcode, and your unique access PIN, as well as an email with a calendar invite.

A live webcast can be accessed at https://edge.media–server.com/mmc/p/bt67nb59.

A replay of the conference call will also be available on the Company’s investor relations website at https://ir.antalpha.com.

About Antalpha
Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to institutions in the digital asset industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real–time data.

About Aurelion
Aurelion is NASDAQ’s first Tether Gold (XAU₮) treasury. It combines the stability of physical gold with the efficiency of blockchain, providing investors access to tokenized gold reserve that could serve as a safe haven to inflation, currency devaluation and crypto volatility. In parallel, Aurelion will continue its wealth management and asset management services.

About Tether Gold (XAU₮)
Tether Gold (XAU₮) is a digital asset offered by TG Commodities S.A. de C.V. One full XAU₮ token represents one troy fine ounce of gold on a London Good Delivery bar. XAU₮ is available as an ERC–20 token on the Ethereum blockchain. The token can be traded or moved easily 24/7. XAU₮ allocated gold is identifiable with a unique serial number, purity, and weight, and is redeemable.

About Antalpha RWA Hub
Antalpha RWA Hub is Antalpha's dedicated Real–World Assets (“RWA”) infrastructure platform, currently focused on providing liquidity and services for gold–based RWAs.

Contacts
Investor Contact: [email protected] 

Safe Harbor Statement
This press release contains statements that may constitute “forward–looking” statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward–looking statements can be identified by terminology such as: “anticipate,” “aspire,” “intend,” “plan,” “offer,” “goal,” “objective,” “potential,” “seek,” “believe,” “project,” “estimate,” “expect,” “forecast,” “assume,” “strategy,” “target,” “trend,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the relevant business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions, including the anticipated performance of gold, Tether Gold (XAU₮), and any other Gold–related product, and Antalpha and Aurelion’s intention to purchase additional XAU₮. These statements are not historical facts nor assurance of future performance, and include, among others, statements regarding Antalpha’s investment in the Company through the PIPE financing, integration plans, anticipated benefits of the transaction, and Antalpha’s Reserve 2.0 digital treasury strategy. Forward–looking statements also include expectations regarding the purchase, holding, and management of XAU₮, and potential future capital deployment.

Forward–looking statements involve inherent risks and uncertainties that may cause actual results to differ materially, including regulatory review, integration challenges, market price volatility of XAU₮, liquidity risks, counterparty and custodial risks, technological and regulatory developments, accounting treatment, and other factors described in Antalpha’s filings with the SEC. All information in this press release is provided as of the date hereof, and Antalpha undertakes no duty to update any forward–looking statements except as required under applicable law.


GLOBENEWSWIRE (Distribution ID 9544075)

Antalpha investit 150 millions de dollars dans la création de Aurelion Treasury, une nouvelle entité cotée au Nasdaq détenant ses réserves en Tether Gold

Prestige Wealth Inc. (NASDAQ : PWM) deviendra Aurelion Inc. (NASDAQ : AURE), sous réserve de l’autorisation
d’un placement privé de 100 millions de dollars et d’une facilité de crédit de premier rang de 50 autres millions de dollars
à l’initiative d’Antalpha et exclusivement libellés en Tether Gold (XAU₮) au titre de transparence et de résilience.

SINGAPOUR, 11 oct. 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ : ANTA), ci–après « Antalpha », plateforme institutionnelle leader du financement d’actifs numériques, annonce ce jour avoir investi près de 43 millions de dollars comme investisseur principal d’un placement privé en actions cotées et avoir acquis les droits de vote majoritaires de Prestige Wealth Inc. (NASDAQ : PWM ; AURE), ci–après « Aurelion » ou la « Société ». Cette opération pilotée par la direction d’Antalpha est appuyée par la participation d’investisseurs qualifiés comme TG Commodities S.A. de C.V. (« Tether ») ou Kiara Capital Holding Limited (« Kiara Capital »). La Société (NASDAQ : PWM) entend être renommée « Aurelion Inc. », sous réserve des autorisations réglementaires nécessaires et rejoindre le marché boursier sous son nouveau symbole (NASDAQ : AURE) dès le lundi 13 octobre prochain.

« Nous sommes enchantés de collaborer avec Tether, le plus grand émetteur de stablecoins au monde, pour développer l’écosystème de l’or numérique, dans un climat de confiance. Les actifs numériques deviendront plus concrets aux yeux du grand public lorsqu’il sera possible d’entrer dans une bijouterie pour échanger un lingot d’or contre du Tether Gold (XAU₮). En fondant le Antalpha RWA Hub, nous comptons bien proposer de nouvelles solutions et de nouveaux services similaires visant à relever la liquidité et l’offre de produits de Tether Gold (XAU₮) » explique Paul Liang, directeur financier d’Antalpha.

« En intégrant Aurelion Treasury à Antalpha RWA Hub, nous sommes enthousiastes à l’idée de fonder la première société cotée au NASDAQ à constituer sa trésorerie avec de l’or tokenisé Tether Gold (XAU₮), dont l’importance dans l’environnement des actifs numériques devient stratégique. Dans un monde en proie à l’inflation, à la dévaluation des monnaies et à la volatilité crypto, l’or reste une valeur refuge pour les particuliers et les institutions. Plateforme de financement d’actifs numériques de premier ordre, Antalpha démontre un intérêt à renforcer son propre bilan grâce à une importante réserve d’or Tether Gold (XAU₮) tokenisé dans le but d’améliorer sa résilience financière », poursuit–il.

Raisonnement stratégique
Antalpha Reserve 2.0 s’appuie sur un programme pilote lancé plus tôt dans l’année, au moment où la Société a acheté 20 millions de dollars de Tether Gold (XAU₮). Début octobre, Antalpha a annoncé le début d’un partenariat avec Tether en vue d’instituer Antalpha RWA Hub et d’élargir l’accès du public à Tether Gold (XAU₮). L’investissement de 43 millions de dollars dans un placement privé en actions cotées s’inscrit dans la stratégie Reserve 2.0 d’Antalpha, à savoir constituer une réserve en or numérique adossée d’une infrastructure institutionnelle, d’une gouvernance solide et d’une meilleure transparence en étoffant sa réserve en Tether Gold (XAU₮).

L’or a servi de référence absolue pendant plus de 5 000 ans, et a constitué de tout temps une couverture naturelle contre la volatilité macroéconomique et les incertitudes politiques. Son rapport négatif avec l’indice U.S. Dollar Index (DXY) durant les crises mondiales et les cycles inflationnistes et sa nature de valeur refuge face à la volatilité des cryptomonnaies renforcent sa valeur sur la blockchain.

La crypto Tether Gold (XAU₮) répond à ces fragilités puisqu’elle est intégralement adossée à de l’or réel et peut s’échanger contre des lingots standard de la LBMA stockés en Suisse. Depuis son lancement en 2020, près de 7 tonnes d’or ont été achetées pour garantir Tether Gold (XAU₮), proposant ainsi une transparence, une vérifiabilité et une liquidité de niveau institutionnel. En s’engageant à exclusivement constituer la réserve de trésorerie d’Aurelion en Tether Gold (XAU₮), Antalpha vise à nuancer la volatilité, privilégier la liquidité et renforcer sa résilience financière, conformément à son approche de gestion des risques.

Points clés de l’opération
Antalpha a investi près de 43 millions de dollars dans un placement privé en actions cotées valorisé à quelque 100 millions de dollars et visant à financer Aurelion, à l’appui de la participation Kiara Capital à hauteur de 6 millions de dollars et de celle de Tether à concurrence de 15 millions de dollars. À l’issue de cette opération, Antalpha détient environ 32,4 % du capital d’Aurelion (soit approximativement 73,1 % des droits de vote), contre une part de 8,6 % pour Kiara Capital (soit environ 18,9 % des droits de vote). Ce constat s’établit selon les actions de la Société en circulation et en supposant qu’aucun bon de souscription du placement privé en actions cotées ne soit exercé. À l’appui de projets de levées de fonds supplémentaires visant une part supérieure de Tether Gold (XAU₮) en ligne de mire, Aurelion estime que son actionnariat concentré peut lui apporter plus de stabilité et lui assurer des opérations plus fluides.

Détails de la conférence téléphonique
La direction d’Antalpha organisera une conférence téléphonique le 14 octobre 2025 à 8h30, heure de l’Est des États–Unis, en vue d’ouvrir les échanges sur l’opération.

Pour y assister, nous vous invitons à vous y inscrire à l’avance en suivant ce lien : https://register–conf.media–server.com/register/BIdf5d33a26d64454da01f41f3d6c9610e. Une fois inscrit, vous recevrez le numéro à composer et le code d’accès, votre code PIN personnel et une invitation calendrier par e–mail.

Une retransmission en direct sera disponible à ce lien : https://edge.media–server.com/mmc/p/bt67nb59.

Une diffusion en replay de la conférence sera également disponible sur la page dédiée aux relations investisseurs du site Internet de la Société, à savoir https://ir.antalpha.com.

À propos d’Antalpha
Antalpha est une fintech de première importance spécialisée dans les solutions de financement, de technologie et de gestion des risques propres aux institutions exerçant leurs activités dans le secteur des actifs numériques. Antalpha propose des prêts sur la chaîne d’approvisionnement en Bitcoin et des prêts sur marge depuis sa plateforme Antalpha Prime. Celle–ci permet à ses clients de gérer les prêts en actifs numériques et d’en suivre les garanties en quasi temps réel.

À propos d’Aurelion
Aurelion est la toute première société cotée au NASDAQ dont la réserve en trésorerie est exclusivement constituée en Tether Gold (XAU₮). L’entreprise allie la stabilité de l’or physique à l’efficacité de la blockchain et propose un accès à une réserve d’or tokenisée pouvant servir de valeur refuge contre l’inflation, la dévaluation monétaire et la volatilité des cryptomonnaies aux investisseurs. En parallèle, Aurelion poursuivra également ses activités de gestion de patrimoine et de gestion d’actifs.

À propos de Tether Gold (XAU₮)
XAU₮ est un actif numérique émis par TG Commodities S.A. de C.V. Chaque jeton XAU₮ vaut une once troy d’or fin conforme à la norme « Good Delivery » de la LBMA. L’actif XAU₮ est disponible sous forme de jeton ERC–20 sur la blockchain Ethereum. Il peut s’échanger ou se transférer à tout moment. L’or alloué à chaque XAU₮ est identifiable par un numéro de série unique, une pureté et un poids propres. Il est également pleinement échangeable.

À propos deAntalpha RWA Hub
Antalpha RWA Hub est la plateforme dédiée aux actifs du monde réel d’Antalpha (ou « RWA », de l’anglais Real World Asset), actuellement axée sur la fourniture de liquidités et de services spécifiques aux actifs réels adossés à l’or.

Coordonnées
Investisseurs : [email protected]

Dispositions dites « Safe Harbor »
Le présent communiqué de presse contient des « déclarations prospectives » au sens des dispositions relevant de la sphère de sécurité propre à la loi fédérale américaine Private Securities Litigation Reform Act de 1995. Les déclarations prospectives se caractérisent par l’emploi de termes tels que « anticiper », « aspirer à », « entendre », « prévoir », « proposer », « objectif », « potentiel », « envisager », « croire », « projeter », « estimer », « provisionner », « sous–tendre », « stratégie », « cible », « tendance », « à l’avenir », « probable », « serait », « devrait » ou « sera » et d’autres expressions de même sens évoquant des situations à venir. Aucune déclaration prospective ne relève de faits historiques ni ne préjuge de futures performances. Elles reposent uniquement sur les convictions, attentes et hypothèses actuelles concernant l’évolution de l’activité de la Société nouvellement fondée, les plans et stratégies à venir, les prévisions, les événements anticipés et les tendances connexes, la conjoncture économique et d’autres conditions à venir, y compris la performance attendue de l’or, du Tether Gold (XAU₮), et de tout autre produit adossé à l’or, et l’intention d’Antalpha et d’Aurelion d’acquérir des XAU₮ supplémentaires. Elles ne constituent ni des faits historiques ni des garanties de performance future. Elles expriment notamment des déclarations relatives à l’investissement d’Antalpha dans la Société réalisé par le biais d’un placement privé en actions cotées, aux projections d’intégration, aux bénéfices attendus de l’opération, et à la stratégie de trésorerie numérique Reserve 2.0 retenue par Antalpha. Les déclarations prospectives se rapportent en outre aux attentes relatives à l’achat, la détention et la gestion de XAU₮, ainsi qu’aux éventuelles allocations futures du capital.

Elles sont assujetties à des risques et incertitudes propres, susceptibles d’entraîner des écarts sensibles entre les prévisions et les résultats réels. Ces risques visent plus particulièrement les revues réglementaires, les enjeux d’intégration, la volatilité des cours du jeton XAU₮, les risques de liquidité, les risques liés aux contreparties et aux dépositaires, les évolutions de nature technologique et réglementaire, le traitement comptable, et d’autres facteurs détaillés dans les documents déposés par Antalpha auprès de la SEC. Toutes les données contenues dans ce communiqué sont exclusivement valables à leur date de publication, et Antalpha décline toute obligation de les mettre à jour, sauf si les lois applicables l’exigent.


GLOBENEWSWIRE (Distribution ID 9544075)

Antalpha Anchors $150 Million Financing in Aurelion Treasury; Initiating NASDAQ’s First Tether Gold Treasury

Prestige Wealth Inc. (NASDAQ: PWM) Plans to be Renamed to Aurelion Inc. (NASDAQ: AURE) Subject to Approvals
$100 Million Private Placement & $50 Million Senior Debt Facility
Antalpha Anchors Aurelion Treasury, Exclusively in Tether Gold (XAU₮) for Resilience and Transparency

SINGAPORE, Oct. 10, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (NASDAQ: ANTA) (“Antalpha”), a leading institutional digital asset financing platform, today announced that it has invested approximately $43 million as lead investor and acquired controlling voting rights in Prestige Wealth Inc. (NASDAQ: PWM; AURE) (“Aurelion” or the “Company”) through participation in a committed private investment in public equity (“PIPE”), alongside accredited investors including TG Commodities S.A. de C.V. (“Tether”) and Kiara Capital Holding Limited (“Kiara Capital”), invested by Antalpha’s management. The Company (NASDAQ: PWM) is expected to be renamed as “Aurelion Inc.”, subject to approvals, and will trade under the new ticker (NASDAQ: AURE) beginning Monday, October 13, 2025.

“We are excited to collaborate with Tether, the largest stablecoin company in the world, to expand the trusted digital gold ecosystem. Digital assets will be more tangible to many when one can walk into a jewelry store and redeem a gold bar with Tether Gold (XAU₮). Through Antalpha RWA Hub, we hope to deliver new capabilities and services like this that will increase the liquidity and product offerings of Tether Gold (XAU₮),” said Paul Liang, CFO of Antalpha.

“Adding to Antalpha RWA Hub, we are excited to anchor Aurelion Treasury, the first pure–play NASDAQ Tether Gold (XAU₮) Treasury, to increase access to tokenized gold, which has strategic importance in the digital asset world. People and institutions need a safe haven to safeguard against inflation, fiat currency devaluation and crypto volatility. As a leading digital asset financing platform, Antalpha has common interest to fortify our own balance sheet with a significant gold reserve through Tether Gold (XAU₮) to improve collateral resilience,” continued Paul Liang.

Strategic Rationale
Antalpha Reserve 2.0 builds on Antalpha’s pilot program earlier this year when it acquired $20 million of Tether Gold (XAU₮). In early October, we announced a collaboration with Tether to launch Antalpha RWA Hub to increase access to Tether Gold (XAU₮). The $43 million PIPE lead investment in Aurelion Treasury represents the next phase of Reserve 2.0: scaling Antalpha’s Tether Gold (XAU₮) reserve with institutional infrastructure, governance and transparency.

Gold has served as the ultimate benchmark of value for more than 5,000 years, consistently providing a natural hedge amid macroeconomic volatility and political uncertainty. Its negative correlation to the U.S. dollar index (DXY) amidst global crises and inflationary cycles as well as serving as a safe haven to crypto volatility highlight the value of gold on the blockchain.

Tether Gold (XAU₮) addresses these vulnerabilities by being 100% physically backed and redeemable for LBMA–standard bullions stored in Switzerland. Since launching in 2020, approximately 7 tons of gold have been acquired to back Tether Gold (XAU₮), providing institutional–grade transparency, verifiability and liquidity. By committing to Tether Gold (XAU₮) as Aurelion’s sole treasury reserve, Antalpha aims to smooth volatility, preserve liquidity and increase collateral resilience, which supports Antalpha’s management philosophy of risk management first.

Transaction Highlights
Antalpha invested approximately $43 million in Aurelion’s approximately $100 million PIPE, along with accredited investors, including Kiara Capital for $6 million and Tether for $15 million. Following this transaction, Antalpha holds a stake of approximately 32.4% (or approximately 73.1% of the voting rights) and Kiara Capital holds a stake of approximately 8.6% (or approximately 18.9% of the voting rights) in Aurelion, based on the Company’s outstanding shares and assuming no exercise of PIPE warrants. With plans to continue fundraising to purchase additional Tether Gold (XAU₮), Aurelion believes its concentrated shareholding can provide more stability and ensure smoother operations.

Conference Call Information
Antalpha leadership will host a conference call at 8:30 am U.S. Eastern Standard Time on October 14, 2025 to discuss the transaction.

To attend, please register in advance at: https://register–conf.media–server.com/register/BIdf5d33a26d64454da01f41f3d6c9610e. Upon registration, you will receive the dial–in number, passcode, and your unique access PIN, as well as an email with a calendar invite.

A live webcast can be accessed at https://edge.media–server.com/mmc/p/bt67nb59.

A replay of the conference call will also be available on the Company’s investor relations website at https://ir.antalpha.com.

About Antalpha
Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to institutions in the digital asset industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real–time data.

About Aurelion
Aurelion is NASDAQ’s first Tether Gold (XAU₮) treasury. It combines the stability of physical gold with the efficiency of blockchain, providing investors access to tokenized gold reserve that could serve as a safe haven to inflation, currency devaluation and crypto volatility. In parallel, Aurelion will continue its wealth management and asset management services.

About Tether Gold (XAU₮)
Tether Gold (XAU₮) is a digital asset offered by TG Commodities S.A. de C.V. One full XAU₮ token represents one troy fine ounce of gold on a London Good Delivery bar. XAU₮ is available as an ERC–20 token on the Ethereum blockchain. The token can be traded or moved easily 24/7. XAU₮ allocated gold is identifiable with a unique serial number, purity, and weight, and is redeemable.

About Antalpha RWA Hub
Antalpha RWA Hub is Antalpha's dedicated Real–World Assets (“RWA”) infrastructure platform, currently focused on providing liquidity and services for gold–based RWAs.

Contacts
Investor Contact: [email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward–looking” statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward–looking statements can be identified by terminology such as: “anticipate,” “aspire,” “intend,” “plan,” “offer,” “goal,” “objective,” “potential,” “seek,” “believe,” “project,” “estimate,” “expect,” “forecast,” “assume,” “strategy,” “target,” “trend,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the relevant business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions, including the anticipated performance of gold, Tether Gold (XAU₮), and any other Gold–related product, and Antalpha and Aurelion’s intention to purchase additional XAU₮. These statements are not historical facts nor assurance of future performance, and include, among others, statements regarding Antalpha’s investment in the Company through the PIPE financing, integration plans, anticipated benefits of the transaction, and Antalpha’s Reserve 2.0 digital treasury strategy. Forward–looking statements also include expectations regarding the purchase, holding, and management of XAU₮, and potential future capital deployment.

Forward–looking statements involve inherent risks and uncertainties that may cause actual results to differ materially, including regulatory review, integration challenges, market price volatility of XAU₮, liquidity risks, counterparty and custodial risks, technological and regulatory developments, accounting treatment, and other factors described in Antalpha’s filings with the SEC. All information in this press release is provided as of the date hereof, and Antalpha undertakes no duty to update any forward–looking statements except as required under applicable law.


GLOBENEWSWIRE (Distribution ID 9543594)

Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de directeur général

 NEW YORK, 09 oct. 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, une société de biotechnologie qui mise sur les circuits neuronaux pour rétablir l’homéostasie immunitaire chez les patients malades, a été lancée aujourd’hui avec un financement de série A de 101 millions de dollars mené par The Column Group (TCG), DCVC Bio et Lux Capital, avec la participation de la Fondation Gates et d’Alexandria Venture Investments. Parallèlement à son lancement, Nilo a annoncé la nomination de Kim Seth, Ph.D., au poste de directeur général et membre du conseil d’administration.

Fondée par des scientifiques de renommée mondiale, Charles Zuker, Ph.D. (Université Columbia), Ruslan Medzhitov, Ph.D. (Université Yale) et Steve Liberles, Ph.D. (Université Harvard), Nilo a été créée en collaboration avec TCG afin de traduire des découvertes scientifiques révolutionnaires en neuro–immunologie en nouvelles stratégies thérapeutiques. Le Dr Seth rejoint le directeur scientifique Laurens Kruidenier, Ph.D., pour mener la transition de l’entreprise vers sa prochaine phase de croissance. Le financement permet la création des laboratoires de Nilo à New York, la croissance de son équipe de recherche et développement interdisciplinaire et l’avancement des programmes précliniques de l’entreprise.

Nilo développe des médicaments exploitant les circuits neuronaux dans le but de rétablir l’homéostasie immunitaire au niveau central, offrant ainsi une approche différenciée de l’immunomodulation allant bien au–delà de l’immunosuppression conventionnelle. La société s’appuie sur les découvertes scientifiques fondamentales du laboratoire de Charles Zuker, Ph.D. (responsable de recherche à l’université Columbia et chercheur à l’Institut médical Howard Hughes), qui a identifié des neurones spécifiques du nerf vague régulant l’activation immunitaire systémique et l’inflammation. En ciblant ces circuits cerveau–corps « régulateurs principaux », Nilo utilise son approche thérapeutique novatrice pour moduler plusieurs voies immunitaires de manière concertée, réduisant ainsi le risque de résistance thérapeutique et élargissant l’impact potentiel sur un large éventail de maladies auto–immunes et inflammatoires. Cette approche répond à un besoin important non satisfait.

Le Dr Seth apporte plus de 25 ans d’expérience dans l’industrie biopharmaceutique, ayant occupé des postes opérationnels dans plusieurs sociétés biotechnologiques en phase de démarrage et cotées en bourse, ainsi que dans de grandes sociétés pharmaceutiques. Il possède une vaste expertise dans la création d’entreprises, la stratégie et les opérations de R&D, le développement commercial, la finance et les marchés de capitaux. Avant de rejoindre Nilo, le Dr Seth a occupé le poste de directeur commercial chez Repare Therapeutics, une société spécialisée dans l’oncologie de précision, où, en tant que membre de l’équipe de direction, il a joué un rôle déterminant dans le développement de la société, depuis le financement de série A jusqu’au financement de série B et à l’introduction en bourse. Il était chargé de mettre en place les activités commerciales de l’entreprise aux États–Unis dont il a dirigé le développement commercial afin de générer plus de 250 millions de dollars de financement grâce à une série de partenariats mondiaux en matière de plateformes, d’actifs et de cliniques, représentant une valeur potentielle totale de plus de 4 milliards de dollars. Avant de rejoindre Repare, le Dr Seth a occupé des postes de direction dans les domaines du développement commercial, de la stratégie et des opérations au sein de plusieurs entreprises biopharmaceutiques, dont Pfizer, et a été analyste de recherche dans le domaine des produits pharmaceutiques à grande capitalisation et des produits pharmaceutiques spécialisés chez Goldman Sachs. Il a obtenu une licence en économie avec mention très bien au Harvard College et un doctorat en neurobiologie à la Division des sciences médicales de l’université de Harvard.

Le Dr Seth rejoint Laurens Kruidenier, Ph.D., directeur scientifique, un leader accompli dans le domaine de l’immunologie et de la découverte de médicaments. Le Dr Kruidenier a précédemment occupé le poste de directeur scientifique chez Cellarity et Prometheus Biosciences (racheté par Merck), où il a fait progresser plusieurs thérapies innovantes, du concept à la clinique, dans le domaine des maladies auto–immunes et inflammatoires. Au début de sa carrière chez Takeda Pharmaceuticals et GSK, il a dirigé des équipes de recherche préclinique et de découverte, ainsi que la stratégie de développement commercial. Il a obtenu son doctorat en immunologie à l’université de Leyde et ses recherches ont été publiées dans des revues scientifiques de premier plan, notamment Nature.

« Nilo se trouve à un moment charnière », a déclaré Laurens Kruidenier, Ph.D., directeur scientifique de Nilo Therapeutics. « Le leadership et l’expérience de Kim permettront d’accélérer notre mission consistant à traduire les avancées révolutionnaires en neuro–immunologie en médicaments pouvant bénéficier aux patients atteints d’un large éventail de maladies immunitaires. »

« Nous sommes ravis d’accueillir Kim au poste de PDG », a déclaré le Dr Tim Kutzkey, associé directeur chez The Column Group. « Fort d’une expérience éprouvée dans l’accompagnement d’entreprises depuis leurs débuts jusqu’à leur introduction en bourse et dans la mise en œuvre réussie de programmes, Kim apporte à la fois une grande expérience et une vision. Sa passion pour la transformation de la science audacieuse en médicaments révolutionnaires fait de lui le partenaire idéal pour compléter le leadership scientifique de Laurens et mener Nilo vers sa prochaine phase de croissance. »

« C’est un honneur de rejoindre l’équipe incroyablement talentueuse et engagée de Nilo », a déclaré Kim Seth, PDG de Nilo Therapeutics. « Avec Laurens, nos fondateurs scientifiques de renommée mondiale et nos investisseurs, nous bâtissons une entreprise bien placée pour fournir une nouvelle génération de traitement exploitant l’axe cerveau–immunité afin de transformer le traitement des maladies auto–immunes et inflammatoires. »

À propos de Nilo Therapeutics

Nilo Therapeutics est une société de biotechnologie qui développe une nouvelle classe de médicaments exploitant les circuits neuronaux dans le but de rétablir l’homéostasie immunitaire chez les patients malades. En ciblant les principaux circuits cerveau–corps responsables de la régulation centrale de l’inflammation systémique, Nilo est à l’avant–garde d’une approche différenciée de l’immunomodulation qui pourrait permettre de traiter un large éventail de maladies auto–immunes et inflammatoires. Une approche qui répond à un besoin important non satisfait. La société a son siège à New York, NY. www.nilotx.com

Pour plus d’informations, veuillez contacter [email protected].


GLOBENEWSWIRE (Distribution ID 9542701)

Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, ein Biotechnologieunternehmen, das neuronale Schaltkreise nutzt, um die Immunhomöostase bei Krankheiten wiederherzustellen, startete heute mit einer Serie–A–Finanzierung in Höhe von 101 Mio. USD unter der Leitung von The Column Group (TCG), DCVC Bio und Lux Capital, unter Beteiligung der Gates Foundation und Alexandria Venture Investments. Zeitgleich mit der Markteinführung hat Nilo die Ernennung von Dr. Kim Seth zum Chief Executive Officer und Vorstandsmitglied bekanntgegeben.

Nilo wurde von den weltweit führenden Wissenschaftlern Dr. Charles Zuker (Columbia University), Dr. Ruslan Medzhitov (Yale University) und Dr. Steve Liberles (Harvard University) gegründet und entstand in Zusammenarbeit mit TCG, um bahnbrechende wissenschaftliche Erkenntnisse in der Neuroimmunologie in neue therapeutische Strategien umzusetzen. Dr. Seth wird gemeinsam mit Chief Scientific Officer Dr. Laurens Kruidenier die Umwandlung des Unternehmens von einem Stealth–Unternehmen in die nächste Wachstumsphase leiten. Die Finanzierung dient der Einrichtung von Nilos Labors in New York City, dem Ausbau seines interdisziplinären Forschungs– und Entwicklungsteams und der Weiterentwicklung der präklinischen Programme des Unternehmens.

Nilo entwickelt Medikamente, die neuronale Schaltkreise nutzen, um die Immunhomöostase zentral wiederherzustellen. Damit bietet das Unternehmen einen differenzierten Ansatz zur Immunmodulation, der über die herkömmliche Immunsuppression hinausgeht. Das Unternehmen baut auf bahnbrechenden wissenschaftlichen Entdeckungen aus dem Labor von Dr. Charles Zuker (Hauptforscher an der Columbia University und Forscher am Howard Hughes Medical Institute) auf, der bestimmte vagale Neuronen identifiziert hat, die die systemische Immunaktivierung und Entzündung regulieren. Durch die gezielte Beeinflussung dieser zentralen „Master–Regulator“–Kreisläufe zwischen Gehirn und Körper nutzt Nilo seinen neuartigen therapeutischen Ansatz, um mehrere Immunwege gleichzeitig zu modulieren, wodurch das Risiko einer Therapieresistenz verringert und die potenzielle Wirkung auf ein breites Spektrum von Autoimmun– und Entzündungskrankheiten mit großem ungedecktem Bedarf erweitert wird.

Dr. Seth verfügt über mehr als 25 Jahre Erfahrung in der Biopharmaindustrie und war in verschiedenen Führungspositionen bei mehreren Start–ups und börsennotierten Biotech–Unternehmen sowie großen Pharmaunternehmen tätig. Er hat zudem umfassende Fachkenntnisse in den Bereichen Unternehmensaufbau, Strategie und F&E–Aktivitäten, Geschäftsentwicklung, Finanzen und Kapitalmärkte. Vor seiner Tätigkeit bei Nilo war Dr. Seth als Chief Business Officer bei Repare Therapeutics tätig, einem Unternehmen im Bereich der Präzisionsonkologie. Dort war er Mitglied der Geschäftsleitung und maßgeblich daran beteiligt, das Unternehmen von der Pre–Series–A–Finanzierungsrunde über die Series–B–Finanzierungsrunde bis hin zum Börsengang zu skalieren. Er war für den Aufbau des US–Geschäfts des Unternehmens verantwortlich und leitete die Geschäftsentwicklung, um über eine Reihe globaler Plattform–, Vermögens– und klinischer Partnerschaften Finanzierungen in Höhe von über 250 Mio. USD zu generieren, was einem potenziellen Gesamtwert von über 4 Mrd. USD entspricht. Vor seiner Tätigkeit bei Repare hatte Dr. Seth Führungspositionen in den Bereichen Geschäftsentwicklung, Strategie und Betrieb bei einer Reihe von Biopharmaunternehmen, darunter Pfizer, inne und war Research Analyst für Large–Cap–Pharmaunternehmen/Spezialpharmaunternehmen bei Goldman Sachs. Er erwarb seinen BA cum laude in Wirtschaftswissenschaften am Harvard College und seinen Ph.D. in Neurobiologie in der Abteilung für Medizinische Wissenschaften an der Harvard University.

Dr. Seth schließt sich Dr. Laurens Kruidenier, Chief Scientific Officer, einem erfahrenen Experten für Immunologie und Arzneimittelforschung, an. Dr. Kruidenier war zuvor als CSO bei Cellarity und Prometheus Biosciences (von Merck übernommen) tätig, wo er mehrere innovative Therapien für Autoimmun– und Entzündungskrankheiten vom Konzept bis zur klinischen Anwendung vorantrieb. Zu Beginn seiner Karriere bei Takeda Pharmaceuticals und GSK leitete er Teams für präklinische Forschung und Entdeckungsforschung sowie die Strategie für Geschäftsentwicklung. Er promovierte in Immunologie an der Universität Leiden und seine Forschungsergebnisse wurden in führenden wissenschaftlichen Fachzeitschriften, darunter Nature, veröffentlicht.

„Nilo befindet sich in einer Phase des Wandels“, so Dr. Laurens Kruidenier, Chief Scientific Officer von Nilo Therapeutics. „Die Führungsqualitäten und Erfahrung von Dr. Seth werden unsere Mission beschleunigen, bahnbrechende Erkenntnisse aus der Neuroimmunologie in Medikamente umzusetzen, von denen Patienten mit einer Vielzahl von immunbedingten Erkrankungen profitieren könnten.“

„Wir freuen uns sehr, Dr. Seth als CEO begrüßen zu dürfen“, so Dr. Tim Kutzkey, Managing Partner bei The Column Group. „Mit seiner Erfolgsbilanz bei der Begleitung von Unternehmen von ihren Anfängen bis zum Börsengang und der erfolgreichen Umsetzung von Programmen bringt Dr. Seth sowohl Weitblick als auch Visionen mit. Seine Leidenschaft, bahnbrechende wissenschaftliche Erkenntnisse in innovative Medikamente umzusetzen, macht ihn zum idealen Partner, um Laurens' wissenschaftliche Führungsrolle zu ergänzen und Nilo in die nächste Wachstumsphase zu führen.“

„Es ist mir eine Ehre, Teil des unglaublich talentierten und engagierten Teams von Nilo zu werden“, so Kim Seth, Chief Executive Officer von Nilo Therapeutics. „Gemeinsam mit Laurens, unseren wissenschaftlichen Gründern von Weltklasse, und unseren Investoren bauen wir ein Unternehmen auf, das eine neue Generation von Therapien entwickeln wird, die die Gehirn–Immun–Achse nutzen, um die Behandlung von Autoimmun– und Entzündungserkrankungen zu revolutionieren.“

Über Nilo Therapeutics

Nilo Therapeutics ist ein Biotechnologieunternehmen, das eine neue Klasse von Medikamenten entwickelt, die neuronale Schaltkreise nutzen, um die Immunhomöostase bei Krankheiten wiederherzustellen. Durch die gezielte Beeinflussung der Master–Regulator–Schaltkreise zwischen Gehirn und Körper, die systemische Entzündungen zentral steuern, leistet Nilo Pionierarbeit bei einem differenzierten Ansatz zur Immunmodulation, der das Potenzial hat, ein breites Spektrum von Autoimmun– und Entzündungskrankheiten mit großem ungedecktem Bedarf zu behandeln. Das Unternehmen hat seinen Hauptsitz in New York, NY. www.nilotx.com

Weitere Informationen erhalten Sie unter [email protected].


GLOBENEWSWIRE (Distribution ID 9542701)

Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO

NOVA YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — A Nilo Therapeutics, uma empresa de biotecnologia que utiliza circuitos neurais para restaurar a homeostase imunológica em doenças, foi lançada hoje com um financiamento de US $101 milhões da Série A liderado por The Column Group (TCG), DCVC Bio e Lux Capital, com participação da Gates Foundation e da Alexandria Venture Investments. No seu lançamento, a Nilo Therapeutics anunciou a nomeação de Kim Seth, Ph.D. como Diretor Executivo e Diretor do Conselho.

Fundada pelos cientistas líderes mundiais Charles Zuker, Ph.D. (Columbia University), Ruslan Medzhitov, Ph.D. (Yale University) e Steve Liberles, Ph.D. (Harvard University), a Nilo foi criada em colaboração com a TCG para transformar conhecimentos científicos inovadores em neuroimunologia em novas estratégias terapêuticas. O Dr. Seth junta–se ao Diretor Científico Laurens Kruidenier, Ph.D., na liderança da transição da empresa da invisibilidade para a sua próxima fase de crescimento. O financiamento estimula o estabelecimento dos laboratórios da Nilo em Nova York, o crescimento da sua equipe interdisciplinar de pesquisa, e o desenvolvimento e o avanço dos programas pré–clínicos da empresa.

A Nilo está desenvolvendo medicamentos que utilizam os circuitos neurais para restaurar centralmente a homeostase imunológica, oferecendo uma abordagem diferenciada à imunomodulação e indo além da imunossupressão convencional. A empresa baseia–se nas descobertas científicas seminais do laboratório de Charles Zuker, Ph.D. (Pesquisador Principal da Columbia University e Pesquisador do Howard Hughes Medical Institute), que identificou neurônios vagais específicos que regulam a ativação imune sistêmica e a inflamação. Ao direcionar esses circuitos centrais do corpo cerebral “regulador mestre”, a Nilo está empregando sua nova abordagem terapêutica para modular múltiplas vias imunológicas em conjunto, reduzindo o risco de resistência terapêutica e ampliando o impacto potencial em um amplo espectro de doenças autoimunes e inflamatórias com grandes necessidades não atendidas.

O Dr. Seth tem mais de 25 anos de experiência no setor biofarmacêutico, tendo ocupado cargos operacionais em várias empresas de biotecnologia em estágio inicial e públicas, e grandes empresas farmacêuticas. Ele tem ampla experiência no estabelecimento de empresas, estratégia e operações de P&D, desenvolvimento de negócios, finanças e mercados de capitais. Antes da Nilo, o Dr. Seth atuou como Diretor de Negócios da Repare Therapeutics, uma empresa de oncologia de precisão, onde foi membro da Equipe de Liderança Executiva e foi fundamental para a expansão da empresa desde a pré–Série A até o financiamento e IPO da Série B. Ele foi responsável por estabelecer as operações comerciais da empresa nos EUA e liderou o desenvolvimento de negócios para gerar mais de US $250 milhões em financiamento por meio de várias plataformas globais, ativos e parcerias clínicas, representando mais de US $4 bilhões em valor potencial total. Antes da Repare, o Dr. Seth ocupou cargos de liderança em BD, estratégia e operações em várias empresas biofarmacêuticas, incluindo a Pfizer, e foi analista de pesquisa de Large–cap Pharmaceuticals/Specialty Pharmaceuticals da Goldman Sachs. Ele obteve seu BA cum laude em Economia no Harvard College e seu Ph.D. em Neurobiologia na Divisão de Ciências Médicas da Harvard University.

O Dr. Seth se junta a Laurens Kruidenier, Ph.D., Diretor Científico, um renomado líder em imunologia e descoberta de medicamentos. O Dr. Kruidenier atuou anteriormente como CSO na Cellarity e na Prometheus Biosciences (adquirida pela Merck), onde avançou várias terapias inovadoras do conceito à clínica em doenças autoimunes e inflamatórias. No início da sua carreira na Takeda Pharmaceuticals e na GSK, ele liderou equipes de pesquisa pré–clínica e de descoberta, bem como a estratégia de desenvolvimento de negócios. Ele obteve seu doutorado em imunologia pela Leiden University e sua pesquisa foi publicada nas principais revistas científicas, incluindo a Nature.

“A Nilo está em um momento de transformação”, disse Laurens Kruidenier, Ph.D., Diretor Científico da Nilo Therapeutics. “A liderança e a experiência de Kim acelerarão nossa missão de transformar a neuroimunologia inovadora em medicamentos que possam beneficiar os pacientes em uma ampla gama de doenças imunológicas.”

“Estamos contentes em receber Kim como CEO”, disse o Dr. Tim Kutzkey, sócio–gerente do The Column Group. “Com um histórico de orientação de empresas desde seus estágios iniciais até o IPO e programas de avanço bem–sucedidos, Kim tem amplitude e visão. Sua paixão por transformar a ciência ousada em medicamentos inovadores faz dele o parceiro ideal para complementar a liderança científica de Laurens e levar a Nilo à sua próxima fase de crescimento.”

“É uma honra me juntar à equipe incrivelmente talentosa e dedicada da Nilo”, disse Kim Seth, Diretor Executivo da Nilo Therapeutics. “Juntamente com Laurens, nossos fundadores científicos de classe mundial e nossos investidores, estamos criando uma empresa posicionada para oferecer uma nova geração de terapias que utilizam o eixo imune cerebral para transformar o tratamento de doenças autoimunes e inflamatórias.”

Sobre a Nilo Therapeutics

A Nilo Therapeutics é uma empresa de biotecnologia que desenvolve uma nova classe de medicamentos que utiliza os circuitos neurais para restaurar a homeostase imune na doença. Ao direcionar circuitos cérebro–corpo reguladores mestres que controlam centralmente a inflamação sistêmica, a Nilo é pioneira com uma abordagem diferenciada para imunomodulação com potencial para tratar um amplo espectro de doenças autoimunes e inflamatórias com grandes necessidades não atendidas. A empresa está localizada em New York, NY. www.nilotx.com

Para mais informações, contacte: [email protected].


GLOBENEWSWIRE (Distribution ID 9542701)

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by The Column Group (TCG), DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. Coinciding with its launch, Nilo announced the appointment of Kim Seth, Ph.D., as Chief Executive Officer and Board director.

Founded by world–leading scientists Charles Zuker, Ph.D. (Columbia University), Ruslan Medzhitov, Ph.D. (Yale University), and Steve Liberles, Ph.D. (Harvard University), Nilo was created in collaboration with TCG to translate groundbreaking scientific insights in neuro–immunology into new therapeutic strategies. Dr. Seth joins Chief Scientific Officer Laurens Kruidenier, Ph.D., in leading the company’s transition from stealth into its next stage of growth. The financing fuels the establishment of Nilo’s laboratories in New York City, growth of its interdisciplinary research and development team, and advancement of the company’s preclinical programs.

Nilo is developing drugs that harness neural circuits to restore immune homeostasis centrally, offering a differentiated approach to immunomodulation and moving beyond conventional immunosuppression. The company builds on seminal scientific discoveries from the laboratory of Charles Zuker, Ph.D. (Columbia University Principal Investigator and Howard Hughes Medical Institute Investigator), which identified specific vagal neurons that regulate systemic immune activation and inflammation. By targeting these central “master regulator” brain–body circuits, Nilo is employing its novel therapeutic approach to modulate multiple immune pathways in concert, reducing the risk of therapeutic resistance and broadening potential impact across a wide spectrum of autoimmune and inflammatory diseases with large unmet need.

Dr. Seth brings over 25 years of biopharma industry experience, with operating roles across multiple early–stage and public biotech companies and large pharma. He has broad expertise in company building, strategy and R&D operations, business development, finance and capital markets. Prior to Nilo, Dr. Seth served as Chief Business Officer at Repare Therapeutics, a precision oncology company, where he was a member of the Executive Leadership Team and was instrumental in scaling the company from pre–Series A through its Series B financing and IPO. He was responsible for establishing the company’s US business operations and led business development to generate over $250 million in financing through a range of global platform, asset, and clinical partnerships, representing over $4 billion in total potential value. Prior to Repare, Dr. Seth held leadership positions in BD, strategy, and operations across a number of biopharma companies including Pfizer, and was a Large–cap Pharmaceuticals /Specialty Pharmaceuticals research analyst at Goldman Sachs. He earned his BA cum laude in Economics at Harvard College, and his Ph.D. in Neurobiology in the Division of Medical Sciences at Harvard University.

Dr. Seth joins Laurens Kruidenier, Ph.D., Chief Scientific Officer, an accomplished immunology and drug discovery leader. Dr. Kruidenier previously served as CSO at Cellarity and at Prometheus Biosciences (acquired by Merck), where he advanced multiple innovative therapies from concept to clinic in autoimmune and inflammatory diseases. Earlier in his career at Takeda Pharmaceuticals and GSK, he led preclinical and discovery research teams as well as business development strategy. He earned his Ph.D. in immunology from Leiden University, and his research has been published in leading scientific journals, including Nature.

“Nilo is at a transformative moment,” said Laurens Kruidenier, Ph.D., Chief Scientific Officer of Nilo Therapeutics. “Kim’s leadership and experience will accelerate our mission to translate breakthrough neuro–immunology into medicines that could benefit patients across a broad range of immune–driven diseases.”

“We are thrilled to welcome Kim as CEO,” said Dr. Tim Kutzkey, Managing Partner at The Column Group. “With a track record of guiding companies from their earliest stages through IPO, and successfully advancing programs, Kim brings both breadth and vision. His passion for translating bold science into breakthrough medicines makes him the ideal partner to complement Laurens’ scientific leadership and lead Nilo into its next phase of growth.”

“It’s an honor to join the incredibly talented and committed team at Nilo,” said Kim Seth, Chief Executive Officer of Nilo Therapeutics. “Together with Laurens, our world–class scientific founders, and our investors, we are building a company positioned to deliver a new generation of therapies that harness the brain–immune axis to transform the treatment of autoimmune and inflammatory conditions.”

About Nilo Therapeutics

Nilo Therapeutics is a biotechnology company developing a new class of medicines that harness neural circuits to restore immune homeostasis in disease. By targeting master regulator brain–body circuits that centrally control systemic inflammation, Nilo is pioneering a differentiated approach to immunomodulation with the potential to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet need. The company is headquartered in New York, NY. www.nilotx.com

For more information, contact [email protected]


GLOBENEWSWIRE (Distribution ID 9542136)

AgDevCo expands its portfolio in Zambia with a new investment in the poultry sector

LONDON, Oct. 02, 2025 (GLOBE NEWSWIRE) — Specialist agriculture investor AgDevCo is pleased to announce its latest investment in Hybrid, an integrated poultry producer located in Zambia.

Hybrid is a leading company in Zambia’s poultry industry, operating a vertically integrated model that spans the entire value chain from breeder farms to processed poultry products. It is part of the African Poultry Development Group which has operations in Zambia, Kenya, Tanzania and Uganda.

Hybrid has more than 1,200 employees and supplies over 2,000 farmers across the country with day–old chicks, contributing to the poultry sector’s development. The company sells processed poultry to major retailers and restaurants across Zambia.

AgDevCo’s investment, a USD10 million senior debt loan, will enable Hybrid to increase its processing capacity by building a modern abattoir which will create another 270 jobs and support the company’s growth.

Jim Henderson, Managing Director at AgDevCo, said:
“We are pleased to be partnering with Hybrid to make this major investment in the Zambian poultry industry. The expansion will drive local job creation and skills development while strengthening regional food security.”

Richard Keeley CEO of Hybrid, said:
“This state–of–the–art facility represents a significant milestone. It will be the largest of its kind in the region, allowing us to supply the Zambian market, where demand is growing rapidly, and export to Lubumbashi, the second–largest city in the DRC. Designed with sustainability at its core, the plant incorporates advanced energy–efficiency measures and wastewater treatment. We are delighted to welcome AgDevCo as a strategic investment partner to make this project a reality.”

AgDevCo is a specialist impact investor operating exclusively in the agriculture sector in Africa. Our mission is to build successful African agribusinesses through long–term investment and support to deliver positive impact at scale. We invest debt and equity in African agribusinesses to create jobs, improve food security, and boost prosperity. With $340 million assets under management, we have made over 88 investments to date (of which 51 exited). Our investments leverage private capital into socially responsible farming and agri–processing businesses in Africa, with benefits for smallholder farmers and local communities.

Contact for media enquiries: Jim Henderson, Managing Director; [email protected]


GLOBENEWSWIRE (Distribution ID 1001131030)

Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Kensana Health Inc. (“Kensana”) today announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS (“GEM”), a Luxembourg–based alternative investment group. Under the agreement, GEM will provide Kensana up to $120 million for a 36–month period following a public listing of Kensana’s ordinary shares (“Investment Period”).

According to the agreement’s terms, Kensana will not be obligated to draw down the full $120 million but can do so in part or in whole at its discretion. Kensana can also set a threshold price as the lowest price at which Kensana may issue shares to GEM under a given drawdown. Kensana will control both the timing and amount of all drawdowns and will issue common shares to GEM on each drawn down from the facility. GEM shall pay 90% of the average daily closing price during the pricing period, which is a 30–day period after Kensana delivers a draw–down notice to GEM. During the lifetime of the investment facility, GEM will not, directly or indirectly, effect any short sale of Kensana’s common shares. GEM is a long–only investor and will not engage in shorting, hedging, or the use of derivatives or synthetic instruments against Kensana’s common shares or the issuance of any warrants.

Ken Clement, founder of Kensana, commented: “It has been determined that 90% of the world’s drugs are synthetically copied from naturally occurring plant compounds. (Bade, et al., 2010. European Journal of Medicinal Chemistry) According to the WHO, up to 80% of the world’s population believes that traditional herbal medicines are safer and have fewer side effects than traditional synthetic pharmaceuticals. Kensana plans to transform modern medicine by integrating its proprietary Artificial Intelligence (AI)–enhanced technology to harness naturally occurring compounds for drug development. Since the COVID pandemic, global markets have had an insatiable appetite for everything natural which positions Kensana and its phytopharmaceutical platform to become a global leader in plant–based medicine. Kensana has already demonstrated this capability through the development of its first FDA drug candidate, KV23A, which has shown incredible efficacy in white label trials outlined in numerous peer–reviewed medical journals. The share subscription facility with GEM demonstrates investor confidence in Kensana’s prospects, as well as GEM’s strategic understanding and vision for emerging markets and industries. This facility will be a very effective financial instrument that will complement our other fundraising efforts ahead of our anticipated NASDAQ listing in 2026.”

About Kensana

Kensana, is a Canadian Phytopharmaceutical company that has created a proprietary Generation 4 AI–enhanced phytobioreactor platform (EMOB) which enables the company to assume leadership in a new industry: Phytopharmaceuticals. The EMOB platform allows Kensana to standardize and convert an abundance of naturally occurring plant and compounds into U.S. FDA registered pharmaceuticals with global respectability. Kensana’s first patented formula is entering an international FDA–registerable Phase 3 clinical trial. Uniquely risk–mitigated, the KV23a formula has already successfully proven safety and efficacy via therapeutic applications in a clinical setting. KV23a is Kensana’s first targeted FDA– registered product within a global chronic wound market worth $300 Billion USD. The Patented Chronic Wound Formula, KV23a, has Proven Medical Efficacy which has been demonstrated in Published peer reviewed medical journals validating KV23a and its efficacy while demonstrating no toxicity issues. Phytopharmaceuticals largely work by targeting specific receptors, interrupting disease pathways and disrupting pathogenic life cycles. The Kensana Platform, EMOB, has the ability to produce proprietary therapies as well as re–engineer synthetic drugs originally derived from natural plant compounds.

Kensana Health has a uniquely risk–mitigated business model and is currently entering a Series C Investment Round. For more information, please visit the website at www.kensana.health or contact Randy Uens at [email protected].

About GEM

GEM is a $3.4 billion, Luxembourg–based alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 590 transactions in over 75 countries. Each investment vehicle has a different degree of operational control, risk–adjusted return, and liquidity profile. Its family of funds and investment vehicles provide GEM and its partners with exposure to Small–Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: www.gemny.com


GLOBENEWSWIRE (Distribution ID 9532205)